Compare stocks

Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, that operates in the pharmaceutical industry with a primary focus on diabetes care. The company develops, manufactures, and markets pharmaceutical products and services, with significant emphasis on insulin and GLP-1 therapy for diabetes management. Novo Nordisk is also involved in the treatment of obesity, rare blood and endocrine disorders, and growth hormone therapy. The company was founded in 1923 and has a substantial international presence, offering products in more than 170 countries. Novo Nordisk's strategic strengths include its extensive research and development capabilities, a strong product pipeline, and a deep commitment to innovation in chronic disease management.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.